Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Biomerica INC (BMRA) USD0.08

Sell:$4.12 Buy:$4.63 Change: $0.12 (2.67%)
Market closed |  Prices as at close on 22 September 2021 | Switch to live prices |
Change: $0.12 (2.67%)
Market closed |  Prices as at close on 22 September 2021 | Switch to live prices |
Change: $0.12 (2.67%)
Market closed |  Prices as at close on 22 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Biomerica, Inc., (Biomerica) is a biomedical technology company. The Company develops, patents, manufactures and markets diagnostic and therapeutic products for the early detection and monitoring of chronic diseases and other medical conditions. The Company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications, by measuring or detecting the of specific bacteria, hormones, antibodies, antigens, or other substances, in a patient body, stools, or blood, saliva or nasal fluid. The Company is engaged in research and development of disruptive, patented diagnostic guided therapy (DGT) products to treat gastrointestinal diseases, such as irritable bowel syndrome (IBS), and other inflammatory diseases.

Contact details

17571 von Karman Ave
United States
+1 (949) 6452111

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$54.79 million
Shares in issue:
12.51 million
Health Care Equipment
United States
US dollar

Key personnel

  • Zackary Irani
    Chairman of the Board, Chief Executive Officer
  • Allen Barbieri
    Lead Independent Executive Vice Chairman of the Board, Corporate Secretary
  • Steven Sloan
    Chief Financial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.